Less than a tenth of individuals who could benefit from GLP-1 drugs such as Wegovy can access them, caution the World Health Organization as it issues its inaugural recommendations on the medications.
With more than one billion individuals worldwide currently obese, it is calling for increased and just availability to this class of drugs.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key obstacles to broad availability to the injections that can assist patients in reducing considerable body mass, explains the body.
GLP-1 Therapy Scarcity
Even in the current best projected outlook, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline encourages governments and firms to expand access, by approaches such as licensing agreements.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Jabs Operate
The injections imitate a natural hormone to delay gastric emptying, reduce hunger and boost the sense of being full so individuals reduce food intake.
Individuals typically see weight reduction within a few weeks of starting on the once-weekly jabs.
Evidence points to patients may regain a significant portion a year later of discontinuing the medication, as their usual appetite come back.
To be carrying excess weight increases your likelihood for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.
